Researchers Discover Inflammatory Switch to Repair Liver Damage

Chronic liver disease often deteriorates due to an overactive immune response, leading to persistent inflammation and scarring. Researchers at Miguel Hernández University in Spain have identified a potential therapeutic target that could help mitigate liver damage. Their findings suggest that altering a single inflammatory switch may improve liver function in patients suffering from cirrhosis.

The immune system’s response can exacerbate liver conditions by triggering immune cells to release harmful molecules. Central to this process are macrophages and monocytes, which can shift the body’s defenses into a more aggressive state. In patients with cirrhosis, healthy liver tissue is gradually replaced by scar tissue, compromising both structure and function. The study highlights the role of Platelet-Activating Factor (PAF), a chemical that promotes inflammation and affects blood vessel dynamics.

This study, led by Rubén Francés Guarinos, aimed to investigate the role of PAF and its receptor, PAF-R, in liver cirrhosis, a condition marked by progressive liver damage and chronic inflammation. “Our main objective was to understand whether blocking this inflammatory pathway could be an effective strategy to improve liver function,” Francés Guarinos explained.

Research involved assessing both patients with cirrhosis and mice with chemically induced cirrhosis. Some mice received treatments that either blocked the PAF-R receptor or inhibited DNA methylation for two weeks prior to surgery. The researchers then analyzed liver immune cells to evaluate the regulation of their DNA activity and measured levels of the PAF receptor.

Findings revealed that in cirrhosis, changes in gene regulation lead to an overactive PAF-R gene, resulting in increased production of PAF-R receptors by liver immune cells. This intensifies inflammation and exacerbates liver damage. Notably, the administration of a drug known as BN-52021 demonstrated a reduction in liver injury and improved blood vessel functionality in the cirrhotic mice. It also helped restore balance in the liver’s immune and inflammatory responses.

“These findings suggest that drugs capable of blocking PAF action, such as BN-52021, could represent a new therapeutic avenue for liver cirrhosis,” stated Enrique Ángel Gomis, another researcher involved in the study. This approach may pave the way for treatments that address the underlying molecular mechanisms rather than just the symptoms of liver disease.

In cirrhosis, the PAF-R gene is activated excessively due to epigenetic changes. Future therapies could focus on correcting these epigenetic controls to prevent the overproduction of PAF-R at its source. This strategy may effectively calm the liver’s immune response, reducing scarring and preserving blood vessel function.

Instead of merely treating the symptoms of cirrhosis, epigenetic-based therapies could offer a more sophisticated and lasting solution to manage inflammation and limit disease progression. The study underscores the growing need for innovative treatments that target the fundamental causes of liver disease.

The research was published in the journal Biomedicine & Pharmacotherapy and emphasizes the importance of understanding inflammatory pathways in developing effective therapies for chronic liver conditions.